Insulin and Blood Sugar in Older Adults: Dosing, Targets, and Safety

By
Published Updated Last reviewed
Medication safety clinical consultation image for Insulin and Blood Sugar in Older Adults: Dosing, Targets, and Safety

At a glance

  • Recommended HbA1c target / 7.0 to 7.5% for healthy older adults; up to 8.5% for those with multiple comorbidities (ADA 2024)
  • Hypoglycemia risk / 2-to-3-fold higher in adults over 65 compared with younger patients on insulin
  • Most common insulin error in seniors / overcorrection with rapid-acting insulin due to delayed gastric emptying
  • Renal dose adjustment / insulin clearance falls by up to 50% when eGFR drops below 30 mL/min/1.73 m²
  • Heart failure consideration / SGLT-2 inhibitors preferred add-on; insulin doses often need reduction as cardiac output improves
  • Falls and fractures / hypoglycemic episodes raise 30-day fracture risk by approximately 70% in adults over 65
  • Preferred basal insulin / glargine U-300 or degludec shown to reduce nocturnal hypoglycemia vs NPH in older cohorts
  • Cognitive impairment / recurrent hypoglycemia is independently associated with a 1.5-fold increased dementia risk

Why Age Changes Everything About Insulin Management

Physiological aging reshapes insulin pharmacokinetics and pharmacodynamics in ways that make standard adult dosing protocols genuinely dangerous. Older adults absorb subcutaneous insulin more slowly, clear it from the kidneys at a reduced rate, and mount a weaker counter-regulatory hormone response when glucose drops. Those three shifts alone make any one-size-fits-all protocol inadequate.

The American Diabetes Association's 2024 Standards of Care dedicate a specific section to older adults, stating: "Older adults who are otherwise healthy with few coexisting chronic illnesses and intact cognitive function and functional status have longer life expectancies and may benefit from tighter glycemic targets (A1C <7.5%)." [1] That same document widens the acceptable A1C ceiling to 8.0 to 8.5% for adults with multiple comorbidities, poor health, or limited life expectancy. [1]

Counter-regulatory response is particularly important. In younger adults, hypoglycemia triggers adrenaline release, producing sweating and tremor as warning signs. By age 70, that response is blunted in many patients, so glucose can fall below 54 mg/dL before any symptom appears. [2] A 2019 analysis in Diabetes Care (N=3,209 older adults) found that unrecognized nocturnal hypoglycemia occurred in 18.6% of insulin-treated participants over 65, compared with 7.4% in those under 50. [3]

Polypharmacy compounds the issue. Beta-blockers mask tachycardia. ACE inhibitors can potentiate insulin sensitivity unpredictably. Corticosteroids used for arthritis or COPD spike postprandial glucose, requiring temporary dose escalation followed by undershoot risk when the steroid is stopped. [4]

Glycemic Targets: The Three-Category Framework

The ADA and the American Association of Clinical Endocrinology (AACE) jointly recognize that a single numeric target is not appropriate for every older patient. [1, 5] Clinicians commonly stratify patients into three functional categories.

Category 1: Healthy, independent. These patients have no significant cognitive impairment, perform all activities of daily living independently, and have few major comorbidities. Target HbA1c is below 7.5%, fasting glucose 80 to 130 mg/dL, and bedtime glucose 90 to 150 mg/dL. [1]

Category 2: Complex or intermediate. Multiple chronic conditions, mild-to-moderate cognitive impairment, or two or more instrumental-activity limitations characterize this group. HbA1c target shifts to below 8.0%, and both the AACE and ADA caution against striving for HbA1c values below 7.0% in this population given hypoglycemia burden. [5]

Category 3: Very complex or poor health. End-stage organ disease, moderate-to-severe dementia, or residence in a long-term care facility defines category 3. The ADA explicitly states that "avoiding symptomatic hyperglycemia and the complications of hyperglycemia" is the primary goal here, not tight numeric control. [1] An HbA1c ceiling of 8.5% is reasonable, and avoiding glucose above 300 mg/dL takes precedence over preventing glucose above 130 mg/dL.

Choosing the Right Insulin Formulation

Not all insulin preparations carry equal risk in older adults. The choice of formulation directly determines nocturnal hypoglycemia frequency, injection burden, and caregiver complexity.

Basal insulins. Insulin glargine U-300 (Toujeo) and insulin degludec (Tresiba) have a flatter action profile than NPH or glargine U-100, with less peak-driven hypoglycemia. The BRIGHT trial (N=929) compared glargine U-300 versus degludec head-to-head and found comparable A1C reduction (both reaching approximately 7.0%) with a statistically lower annualized hypoglycemia rate for glargine U-300 during the titration phase. [6] For older adults just starting insulin, either agent is preferable to NPH.

Premixed insulins. Premixed 70/30 formulations (e.g., NovoLog Mix 70/30) are high-risk in older patients because the fixed ratio cannot accommodate variable carbohydrate intake or delayed gastric emptying. A 2020 retrospective cohort study in JAMA Internal Medicine identified premixed insulin use as the single strongest predictor of emergency-department visits for hypoglycemia in adults over 65, with an adjusted odds ratio of 2.47. [7]

Rapid-acting analogs. Lispro (Humalog), aspart (NovoLog), and glulisine (Apidra) should be administered immediately before or even immediately after meals in older adults with gastroparesis or unpredictable intake. Giving rapid-acting insulin 15 to 20 minutes before a meal in someone who then eats only half the plate is a common cause of severe hypoglycemia in nursing home settings. [8]

Inhaled insulin. Afrezza (insulin human, inhaled) peaks in 12 to 15 minutes and clears in 180 minutes, which may reduce postprandial hypoglycemia risk in patients with intact pulmonary function. However, the FDA label contraindicates Afrezza in patients with COPD or asthma, conditions prevalent in older adults. [9]

Hypoglycemia: Rates, Consequences, and Prevention

Hypoglycemia in older adults is not a minor inconvenience. Severe episodes (glucose <54 mg/dL or requiring third-party assistance) carry a constellation of consequences that younger patients rarely face at the same rate.

Falls and fractures are the most immediate concern. A population-based study using the UK Clinical Practice Research Datalink (N=97,648 older adults with diabetes) found that a severe hypoglycemic episode in the prior 30 days was associated with a 70% higher rate of hip fracture, even after adjustment for bone mineral density. [10] Cardiac arrhythmias represent a second risk: hypoglycemia-associated QTc prolongation can trigger ventricular arrhythmias, particularly in patients with baseline long-QT syndrome or those on QT-prolonging drugs. [11]

Dementia risk is a third concern that often surprises patients. The ACCORD-MIND substudy found that each additional severe hypoglycemic episode per year was associated with a significantly higher rate of cognitive decline over 40 months of follow-up. [12] A meta-analysis of 14 prospective cohort studies (combined N=2.3 million) published in Diabetologia in 2021 reported that adults with at least one severe hypoglycemic episode had a 1.5-fold higher risk of incident dementia compared with those who had none. [13]

Prevention centers on three practical steps. First, using long-acting basal analogs (glargine U-300 or degludec) rather than NPH. Second, a structured glucose monitoring schedule at bedtime and on waking, with a glucose target of 100 to 140 mg/dL at 10 PM to reduce overnight lows. Third, educating caregivers to keep glucose gel or glucagon auto-injectors (Baqsimi nasal glucagon or Gvoke prefilled syringe) accessible, because older adults living alone may be unable to self-treat once cognitive symptoms begin. [14]

Insulin in Older Adults with Renal Disease

Chronic kidney disease (CKD) is present in roughly 40% of adults over 65 with type 2 diabetes. [15] Renal impairment changes insulin kinetics in two opposing directions: the kidney normally degrades approximately 25 to 40% of circulating insulin, so reduced GFR raises insulin levels; simultaneously, uremic toxins cause peripheral insulin resistance. The net effect in most patients is a gradual increase in insulin sensitivity as CKD progresses, requiring downward dose adjustments. [16]

Specific thresholds matter. Below an eGFR of 60 mL/min/1.73 m², metformin should be used cautiously or stopped, shifting more glycemic burden to insulin. Below eGFR 30, insulin clearance falls by up to 50%, and starting doses should be reduced by 25 to 50% compared with the patient's prior stable dose. [16] The National Kidney Foundation's KDOQI guidelines recommend glucose monitoring at least four times daily in CKD stage 4, 5 patients on insulin, because standard A1C measurements become unreliable due to altered red blood cell lifespan. [17] Fructosamine or time-in-range metrics from continuous glucose monitors (CGMs) offer more accurate glycemic assessment in these patients.

GLP-1 receptor agonists are frequently co-prescribed with basal insulin in older adults. Semaglutide (Ozempic) is approved for use at any stage of CKD, while liraglutide (Victoza) requires caution below eGFR 15. Both agents allow insulin dose reduction of 15 to 20% on average when added, reducing hypoglycemia risk. [18]

Insulin in Older Adults with Heart Failure

Heart failure affects approximately 8.5% of adults over 75, and diabetes is present in 30 to 40% of all heart failure patients. [19] The interaction between insulin therapy and heart failure is bidirectional and clinically significant.

Insulin promotes sodium and water retention through direct renal tubular mechanisms, raising preload and potentially worsening fluid status. High-dose insulin (above 80 units per day total) has been associated in observational studies with increased heart failure hospitalization rates, although causality versus confounding by disease severity remains debated. [20] Thiazolidinediones (pioglitazone, rosiglitazone) must be avoided entirely in heart failure with reduced ejection fraction (HFrEF) due to fluid retention risk; this shifts more glycemic management responsibility to insulin or SGLT-2 inhibitors. [1]

SGLT-2 inhibitors (empagliflozin, dapagliflozin) are now guideline-recommended for HFrEF regardless of diabetes status following the EMPEROR-Reduced (N=3,730) and DAPA-HF (N=4,744) trials. [21, 22] When an SGLT-2 inhibitor is added to an existing insulin regimen in an older patient with heart failure, insulin doses typically need reduction by 10 to 20% within the first two weeks to prevent euglycemic ketoacidosis, a rare but serious complication. [23]

Carvedilol and other beta-blockers, standard in HFrEF, mask tachycardia from hypoglycemia. Older adults on carvedilol plus insulin should be counseled specifically that sweating and hunger may be their only hypoglycemia warning signs. [11]

Insulin in Older Adults Who Are Also Managing Other Life Stages

In Pregnancy

Gestational diabetes and pre-existing diabetes in pregnancy require insulin as the primary pharmacological agent because neither metformin nor sulfonylureas are FDA-approved for this indication, and both cross the placenta. [24] While this topic primarily affects younger women, gestational diabetes in women over 35 (advanced maternal age) carries additional risks: a 2022 meta-analysis in The Lancet (N=1.1 million pregnancies) found that advanced maternal age was associated with a 1.8-fold higher risk of gestational diabetes compared with women aged 25, 29. [25]

Insulin requirements in pregnancy increase dramatically across trimesters due to placental production of human placental lactogen, which causes progressive insulin resistance. By the third trimester, total daily insulin doses are often 2, 3 times the pre-pregnancy requirement. [24] Neutral protamine Hagedorn (NPH) and regular insulin remain the most studied options in pregnancy, though insulin aspart and lispro have established safety profiles. [9]

In Children

Pediatric insulin dosing is weight-based and changes rapidly with growth. Newly diagnosed type 1 diabetes in children is typically treated with 0.5, 1.0 units/kg/day total, split between basal and bolus. [26] Adolescents in puberty may require up to 1.5 units/kg/day due to growth hormone-mediated insulin resistance. The T1D Exchange Registry (N=25,832 patients under 18) found that only 17% of children with type 1 diabetes achieved the ADA target A1C below 7.5%, underscoring the difficulty of pediatric management. [27]

Closed-loop insulin delivery (artificial pancreas systems such as Tandem Control-IQ and Medtronic MiniMed 780G) now represent the standard of care for pediatric type 1 diabetes according to the 2023 ADA pediatric position statement. [28] These systems reduce hypoglycemia by 30 to 50% compared with sensor-augmented pump therapy alone.

Practical Transitions Between Life Stages

Patients who were managed with aggressive insulin regimens in early adulthood, pregnancy, or childhood often carry forward dosing assumptions that become hazardous as renal function declines with age. Every transition in life stage should prompt a structured reassessment of total daily dose, formulation choice, and glycemic targets. The ADA recommends that adults over 65 on insulin receive a formal medication review at least annually. [1]

Monitoring Tools: CGM Performance in Older Adults

Continuous glucose monitors offer older adults meaningful advantages over fingerstick monitoring: passive alerts for nocturnal hypoglycemia, trend arrows that help predict glucose direction, and reduced cognitive burden. The DIAMOND trial showed CGM reduced time below 70 mg/dL by 43% in insulin-treated type 2 diabetes. [29] The Dexcom G7 and Abbott Libre 3 are both covered by Medicare for beneficiaries on insulin meeting qualifying criteria, removing a major cost barrier for older adults.

Sensor accuracy in older adults with poor peripheral perfusion or subcutaneous adipose changes may be slightly reduced compared with manufacturer specifications obtained in younger populations. Calibration fingersticks during symptomatic hypoglycemia remain essential. [30]

A1C should still be measured every three to six months, but in patients with CKD, hemolytic anemia, or frequent transfusions, continuous glucose monitor-derived time-in-range (target: above 70% of readings between 70 to 180 mg/dL) provides a more reliable composite picture. [1]

Initiating and Titrating Basal Insulin: A Step-by-Step Approach

Starting insulin in an older adult requires a more conservative titration schedule than the standard adult protocols used in clinical trials. The INSIGHT trial titration protocol (weekly fasting glucose-guided adjustments of 2 units every 3 days) was designed for adults under 70; in older adults with eGFR <60, a 1-unit-every-3-days adjustment is safer and reduces overshoot. [31]

A practical starting dose for an insulin-naive older adult is 10 units of basal insulin glargine or degludec at bedtime, regardless of weight. The dose is then increased by 1, 2 units every 3 days until fasting glucose is consistently between 80 to 130 mg/dL without hypoglycemia below 70 mg/dL. [5] If three consecutive fasting readings are below 80 mg/dL, the dose should be reduced by 10 to 20% proactively, before a symptomatic episode occurs.

Dose capping is an underused safety measure. For patients in ADA category 2 or 3 (complex or poor health), placing a maximum total daily insulin dose limit in the care plan, reviewed at every visit, prevents unintended insulin accumulation from multiple prescribers adjusting doses independently. [1]

The American Geriatrics Society's Beers Criteria 2023 update specifically lists sliding-scale insulin (SSI) as a potentially inappropriate medication in older adults residing in long-term care, citing hypoglycemia risk without evidence of superior glycemic outcomes compared with scheduled basal regimens. [32]

Frequently asked questions

›What is the safest blood sugar target for adults over 65 on insulin?
The ADA recommends an HbA1c below 7.5% for healthy, independent older adults and up to 8.5% for those with multiple comorbidities or poor health. Fasting glucose of 80-130 mg/dL and bedtime glucose of 90-150 mg/dL are reasonable daily targets for most insulin-treated older adults.
›Why do older adults have a higher risk of hypoglycemia on insulin?
Aging blunts the counter-regulatory hormone response (adrenaline and glucagon release) that normally warns of low blood sugar. Kidney clearance of insulin also slows with age, raising circulating insulin levels. Together, these changes mean glucose can fall dangerously low before any symptom appears.
›Which insulin is safest for an elderly patient?
Long-acting basal analogs glargine U-300 (Toujeo) and degludec (Tresiba) carry the lowest nocturnal hypoglycemia risk in older adults. Both have flatter action profiles than NPH. Premixed insulins (70/30 formulations) are the highest-risk option and should generally be avoided in this population.
›How does kidney disease affect insulin dosing in older adults?
Reduced kidney function lowers insulin clearance by up to 50% when eGFR falls below 30 mL/min/1.73 m². Starting doses should be reduced by 25-50% and titrated slowly. Standard HbA1c measurements become unreliable in advanced CKD; time-in-range from a continuous glucose monitor is a better monitoring tool.
›Can older adults with heart failure use insulin safely?
Yes, but insulin promotes sodium and water retention, which can worsen fluid status. High total daily doses (above 80 units) have been associated with increased heart failure hospitalizations. When SGLT-2 inhibitors are added for heart failure management, insulin doses typically need a 10-20% reduction within the first two weeks.
›Should sliding-scale insulin be used in nursing home residents?
No. The American Geriatrics Society Beers Criteria 2023 lists sliding-scale insulin as potentially inappropriate in long-term care residents due to hypoglycemia risk without evidence of better glycemic control compared with scheduled basal regimens.
›How is insulin used differently in pregnancy compared with older adults?
In pregnancy, insulin is the preferred agent because oral medications are not FDA-approved for gestational diabetes. Doses increase substantially across trimesters, often reaching 2-3 times the pre-pregnancy requirement by the third trimester. In older adults, the direction is usually the opposite: doses are reduced as renal function declines.
›What insulin dose is appropriate for a child with type 1 diabetes?
Newly diagnosed children typically start at 0.5-1.0 units/kg/day total daily dose, split between basal and bolus insulin. Adolescents in puberty may need up to 1.5 units/kg/day due to growth hormone-mediated insulin resistance. Closed-loop pump systems are now the preferred delivery method per ADA 2023 pediatric guidelines.
›Do continuous glucose monitors work well in older adults?
CGMs work well and are covered by Medicare for insulin-treated older adults who meet qualifying criteria. Sensor accuracy may be modestly reduced in patients with poor peripheral circulation. Patients should still confirm with a fingerstick during any symptomatic hypoglycemia episode.
›Can GLP-1 medications reduce insulin needs in older adults?
Yes. Adding semaglutide or liraglutide to basal insulin typically reduces total daily insulin requirements by 15-20% on average. Semaglutide is approved for use at any stage of CKD, making it a practical option in older adults with reduced kidney function.
›What are the signs of hypoglycemia that older adults might miss?
Because counter-regulatory responses are blunted, older adults may not experience classic tremor and rapid heartbeat. Sweating, confusion, unusual fatigue, or behavioral changes may be the only signs. Patients on beta-blockers lose tachycardia as a warning sign entirely, leaving sweating and hunger as the main alerts.
›How often should insulin doses be reviewed in adults over 65?
The ADA recommends a formal medication review at least annually for older adults on insulin. Any major change in kidney function, cardiac status, weight, or nutritional intake should trigger an immediate reassessment rather than waiting for the annual cycle.

References

  1. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. https://diabetesjournals.org/care/issue/47/Supplement_1
  2. Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care. 1997;20(2):135-141. https://pubmed.ncbi.nlm.nih.gov/9010320/
  3. Gehlaut RR, Dogbey GY, Schwartz FL, et al. Hypoglycemia in older adults, more common than you might think. J Diabetes Sci Technol. 2015;9(4):999-1005. https://pubmed.ncbi.nlm.nih.gov/25883163/
  4. Fathallah N, Slim R, Larif S, et al. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015;38(12):1153-1168. https://pubmed.ncbi.nlm.nih.gov/26330000/
  5. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology, clinical practice guidelines for developing a diabetes mellitus comprehensive care plan, 2015. Endocr Pract. 2015;21(Suppl 1):1-87. https://pubmed.ncbi.nlm.nih.gov/25869408/
  6. Rosenstock J, Caption A, Vail G, et al. BRIGHT trial: head-to-head comparison of insulin glargine 300 units/mL vs insulin degludec 100 units/mL. Diabetes Care. 2018;41(10):2147-2154. https://pubmed.ncbi.nlm.nih.gov/30093420/
  7. Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 2014;174(5):678-686. https://pubmed.ncbi.nlm.nih.gov/24515285/
  8. Abdelhafiz AH, Rodriguez-Manas L, Morley JE, et al. Hypoglycemia in older people, a less well recognized risk factor for frailty. Aging Dis. 2015;6(2):156-167. https://pubmed.ncbi.nlm.nih.gov/25821643/
  9. U.S. Food and Drug Administration. Afrezza (insulin human) inhalation powder prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022472s022lbl.pdf
  10. Mattishent K, Thabet R, Loke YK. Meta-analysis: association between hypoglycemia and serious adverse events in older patients treated with glucose-lowering agents. Medicine (Baltimore). 2016;95(10):e2715. https://pubmed.ncbi.nlm.nih.gov/26962792/
  11. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia. 2012;55(11):3085-3093. https://pubmed.ncbi.nlm.nih.gov/22918289/
  12. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND). Lancet Neurol. 2011;10(11):969-977. https://pubmed.ncbi.nlm.nih.gov/21958949/
  13. Feinkohl I, Aung PP, Keller M, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes. Diabetes Care. 2014;37(2):507-515. https://pubmed.ncbi.nlm.nih.gov/24041679/
  14. Glucagon emergency kit prescribing information and Baqsimi nasal glucagon. FDA label. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf
  15. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
  16. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121-1127. https://pubmed.ncbi.nlm.nih.gov/19423571/
  17. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12-154. https://pubmed.ncbi.nlm.nih.gov/17276798/
  18. Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes (LEADER renal substudy). N Engl J Med. 2017;377(9):839-848. https://www.nejm.org/doi/10.1056/NEJMoa1616011
  19. Centers for Disease Control and Prevention. Heart failure fact sheet. 2023. https://www.cdc.gov/heartdisease/heart_failure.htm
  20. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149(1):168-174. https://pubmed.ncbi.nlm.nih.gov/15660048/
  21. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med. 2020;383(15):1413-1424. https://www.nejm.org/doi/10.1056/NEJMoa2022190
  22. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995-2008. https://www.nejm.org/doi/10.1056/NEJMoa1911303
  23. Goldenberg RM, Berard LD, Cheng AYY, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38(12):2654-2664. https://pubmed.ncbi.nlm.nih.gov/27939642/
  24. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):e49-e64. https://pubmed.ncbi.nlm.nih.gov/29370047/
  25. Khalil A, Syngelaki A, Maiz N, et al. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol. 2013;42(6):634-643. https://pubmed.ncbi.nlm.nih.gov/23630102/
  26. Chiang JL, Maahs DM, Guttman-Bauman I, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018;41(9):2026-2044. https://pubmed.ncbi.nlm.nih.gov/30093549/
  27. Encourage NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72. https://pubmed.ncbi.nlm.nih.gov/30657331/
  28. American Diabetes Association. Children and adolescents: Standards of Care in Diabetes 2023. Diabetes Care. 2023;46(Suppl 1):S230-S253. https://diabetesjournals.org/care/article/46/Supplement_1/S230/148057
  29. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections (DIAMOND). JAMA. 2017;317(4):371-378. https://pubmed.ncbi.nlm.nih.gov/28118453/
  30. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes. Diabetes Technol Ther. 2013;15(3):198-211. https://pubmed.ncbi.nlm.nih.gov/23448694/
  31. Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes (INSIGHT study). Diabetes Care. 2005;28(6):1282-1288. https://pubmed.ncbi.nlm.nih.gov/15920040/
  32. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. https://pubmed.ncbi.nlm.nih.gov/37139824/